Contract HHSN272201800009I advanced bioscience laboratoriies, INC. Ology base awardprocess development and manufacture of cgmp compliant B19 parvovirus vaccine drug product for use in phase i/II…
Ended Awarded Last action
- Contract number
- 75N93019F00132
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,663,985
Award facts
- Opportunity
-
- RFPDMIDNIAIDNIHAI2017089 Solicitation number
- Contract value 100% obligated
- $1,663,985.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Funding Only Action | -$167,174 | |
| Funding Only Action | -$262,541 | |
| Original award | $2,093,700 |
About this award
This is a $1,663,985.13 firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract supports the process development and cGMP compliant manufacture of a B19 parvovirus vaccine drug product for use in Phase I/II clinical trials. This contract is part of a larger indefinite delivery vehicle (IDV) that ABL holds with NIAID for the Diagnostics Pre-Clinical Services Program, valued at $24 million. The contract does not have a set-aside designation. Through this and other federal contract vehicles, ABL has provided a range of biologics manufacturing, testing, and development services to support infectious disease research and medical countermeasure programs for various NIH institutes.
Description
Contract HHSN272201800009I advanced bioscience laboratoriies, INC. Ology base awardprocess development and manufacture of cgmp compliant B19 parvovirus vaccine drug product for use in phase i/II clinical trialsiid can 84702151,803.970
Quick answers
Who was awarded contract 75N93019F00132?
75N93019F00132 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 14, 2019.
How much is contract 75N93019F00132 worth?
The government has obligated $1,663,985 on 75N93019F00132.
Is contract 75N93019F00132 an order under another contract?
Yes. 75N93019F00132 is a delivery order under 75N93018D00009, an indefinite delivery contract.
Was contract 75N93019F00132 competed?
The extent of competition for 75N93019F00132 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award